EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSCGOG00000014320
Gene Symbol: CACNA1B
3 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSCGOG00000020874
Gene Symbol: CACNA1C
3 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSCGOG00000022718
Gene Symbol: CACNA1D
3 Cross references
212 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSCGOG00000008658
Gene Symbol: CACNA1E
3 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSCGOG00000001010
Gene Symbol: CACNA1E
3 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSCGOG00000018893
Gene Symbol: CACNA1G
2 Cross references
197 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSCGOG00000002999
Gene Symbol: CACNA1H
3 Cross references
210 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSCGOG00000021407
Gene Symbol: CNR1
3 Cross references
135 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSCGOG00000015887
Gene Symbol: LOC115021481
3 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSCGOG00000007337
Gene Symbol: CA12
3 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSCGOG00000005720
Gene Symbol: CA14
3 Cross references
211 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSCGOG00000001661
Gene Symbol: LOC115018025
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).